Overview

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Status:
Active, not recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

This multicenter randomized phase II trial investigates the impact of intense androgen deprivation on radical prostatectomy (RP) pathologic response and radiographic and tissue biomarkers in localized prostate cancer (NCT02903368).

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Janssen Scientific Affairs, LLC

Treatments:

Abiraterone Acetate
Leuprolide
Prednisone